Literature DB >> 18671292

Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis.

Davyd R Hooper1, Mark A Tarnopolsky, Steven K Baker.   

Abstract

We report 2 cases of Lewis-Sumner syndrome (LSS) diagnosed in patients suffering from rheumatoid arthritis undergoing treatment with the antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody infliximab. While experiencing clinical improvement in their arthritic symptoms, both patients experienced sensory deficits and weakness in multiple nerve distributions. They had electrodiagnostic evidence of motor conduction block and subsequent improvement with intravenous immunoglobulin (IVIg). We describe the details of the cases and review the literature on immune-mediated neuropathies associated with anti-TNF-alpha therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671292     DOI: 10.1002/mus.21051

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

Review 1.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

2.  Lewis-Sumner syndrome associated with infliximab therapy for psoriasis.

Authors:  Karen Fernandes de Oliveira; Gladys Aires Martins; Keila Rejane Ferreira Galvão; Patricia Shu Kurizky
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

Review 3.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.